Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors

被引：0
|
作者：
Teixeira, L.
Hickish, T.
Tournigand, C.
Bachet, J.
Bonetti, A.
Rivera, F.
Boni, C.
Tabernero, J.
Andre, T.
De Gramont, A.
机构：
[1] Hop St Antoine, F-75571 Paris, France
[2] Dorset Canc Network, Bournemouth, Dorset, England
[3] Bournemouth Univ, Bournemouth, Dorset, England
[4] Grp Hosp Pitie Salpetriere, F-75634 Paris, France
[5] Dept Med Oncol, Legnago, Italy
[6] Hosp Univ Marques de Valdecilla, Santander, Spain
[7] Arcispedale S Maria Nuova, Reggio Emilia, Italy
[8] Vall dHebron Univ Hosp, Barcelona, Spain
[9] Hop La Pitie Salpetriere, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3524
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Postoperative carcinoembryonic antigen (CEA) association with survival and oxaliplatin benefit in stage II colon cancer (CC): Post hoc analysis of the MOSAIC trial
    Auclin, E.
    Andre, T.
    Taieb, J.
    Banzi, M.
    van Laethem, J-L.
    Tabernero, J.
    Hickish, T.
    de Gramont, A.
    Vernerey, D.
    ANNALS OF ONCOLOGY, 2018, 29 : 154 - 154
  • [42] Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
    Andre, Thierry
    Boni, Corrado
    Navarro, Matilde
    Tabernero, Josep
    Hickish, Tamas
    Topham, Clare
    Bonetti, Andrea
    Clingan, Philip
    Bridgewater, John
    Rivera, Fernando
    de Gramont, Aimery
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3109 - 3116
  • [43] KRAS Mutation is Associated with Worse Prognosis in Stage III or High-risk Stage II Colon Cancer Patients Treated with Adjuvant FOLFOX
    Lee, Dae-Won
    Kim, Kyung Ju
    Han, Sae-Won
    Lee, Hyun Jung
    Rhee, Ye Young
    Bae, Jeong Mo
    Cho, Nam-Yun
    Lee, Kyung-Hun
    Kim, Tae-Yong
    Oh, Do-Youn
    Im, Seock-Ah
    Bang, Yung-Jue
    Jeong, Seung-Yong
    Park, Kyu Joo
    Park, Jae-Gahb
    Kang, Gyeong Hoon
    Kim, Tae-You
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (01) : 187 - 194
  • [44] KRAS Mutation is Associated with Worse Prognosis in Stage III or High-risk Stage II Colon Cancer Patients Treated with Adjuvant FOLFOX
    Dae-Won Lee
    Kyung Ju Kim
    Sae-Won Han
    Hyun Jung Lee
    Ye Young Rhee
    Jeong Mo Bae
    Nam-Yun Cho
    Kyung-Hun Lee
    Tae-Yong Kim
    Do-Youn Oh
    Seock-Ah Im
    Yung-Jue Bang
    Seung-Yong Jeong
    Kyu Joo Park
    Jae-Gahb Park
    Gyeong Hoon Kang
    Tae-You Kim
    Annals of Surgical Oncology, 2015, 22 : 187 - 194
  • [45] Analysis of the benefit of the adjuvant chemotherapy in stage II colon cancer according to the presence of classic poor risk factors: Our experience in Ramon y Cajal Hospital
    Saavedra Serrano, C.
    Villamayor Delgado, M.
    Corral de la Fuente, E.
    Barquin Garcia, A.
    Serrano Domingo, J.
    Martin Huertas, R.
    Martinez Saez, O.
    Longo Munoz, F.
    Reguera Puertas, P.
    Pachon Olmos, V.
    Rodriguez Garrote, M.
    Vaz, M.
    Fuentes, R.
    Carrato, A.
    Ferreiro Monteagudo, R.
    ANNALS OF ONCOLOGY, 2018, 29 : 64 - 64
  • [46] Duration of FOLFOX adjuvant chemotherapy in high-risk stage II and stage III colon cancer with deficient DNA mismatch repair.
    Wu, Zehua
    Hu, Huabin
    Wang, Chao
    Huang, Yan
    Deng, Yanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Identification of high-risk factors as indicators for adjuvant therapy in stage II colon cancer patients treated at a single institution
    Yamaguchi, Keizo
    Ogata, Yutaka
    Akagi, Yoshito
    Shirouzu, Kazuo
    ONCOLOGY LETTERS, 2013, 6 (03) : 659 - 666
  • [48] Tumor sidedness, adjuvant chemotherapy (AC), and other factors affecting survival in patients with stage II colon cancer (CC-II).
    Mukkamalla, Shiva Kumar Reddy
    Huynh, Donny V.
    Somasundar, Ponnandai Sadasivan
    Rathore, Ritesh
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [49] ANALYSIS OF RECURRENCE RISK FACTORS IN PATIENTS WITH STAGE II COLON CANCER.
    Tominaga, T.
    Nagasaki, T.
    Akiyoshi, T.
    Konishi, T.
    Fujimoto, Y.
    Nagayama, S.
    Fukunaga, Y.
    Ueno, M.
    DISEASES OF THE COLON & RECTUM, 2018, 61 (05) : E159 - E159
  • [50] Adjuvant therapy for stage II and III colon cancer in elderly patients: NCDB analysis.
    Master, Samip R.
    Shi, Lawrence
    Shah, Chintan
    Shi, Runhua
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345